F. N. Faruqu is funded by the Malaysian government agency Majlis Amanah Rakyat (MARA). L. Xu is a recipient of the Marie Sklodowska-Curie Individual Fellowships (Horizon 2020) (H2020-MSCA-IF-2016). K. T. Al-Jamal acknowledges funding from BBSRC (BB/J008656/1) and Wellcome Trust (WT103913).&#160;The authors would also like to thank Dr Paul Lavender and Dr David Fear (Department of Respiratory Medicine and Allergy, King&#8217;s College London) for the providing the electroporator.

1. Cell Culture in a Bioreactor Flask
<img alt="Figure 1" class="xfigimg" src="/files/ftp_upload/58814/58814fig1.jpg" /> 
Figure 1: Culture of cells in bioreactor flask for exosome production. (A) Simplified anatomy of the bioreactor flask. (B) Starting culture in the bioreactor flask. See Table of Materials for the composition of normal and exosome-depleted medium (C) Harvesting conditioned medium (CM) and maintenance of culture in the bioreactor flask. <a href="https://www.jove.com/files/ftp_upload/58814/58814fig1large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<ol>
	<li>Culture HEK-293 cells in normal medium (see Table of Materials; 5% CO2, 37 &#176;C) and expand them into 4 x T75 flasks (until 90% confluent).</li>
	<li>Wet the membrane of the bioreactor flask by adding 50-100 mL of normal medium in the medium reservoir of the bioreactor flask.</li>
	<li>Collect all HEK-293 cells from the 4 x T75 and resuspend them in 15 mL of exosome-depleted medium (see Table of Materials).</li>
	<li>Add the HEK-293 cell suspension to the cell compartment of the bioreactor flask using a 20 mL syringe connected to a blunt fill needle (see Table of Materials), with care to remove any bubble that might have formed.</li>
	<li>Fill the medium reservoir of the bioreactor flask with normal medium up to 500 mL and keep the flask in the incubator (5% CO2, 37 &#176;C) for a week.</li>
</ol>
2. Conditioned Medium (CM) Harvesting from the Bioreactor Flask
<ol>
	<li>After 1 week, discard all the medium in the medium reservoir of the bioreactor flask.</li>
	<li>Remove all the medium in the cell compartment (i.e., the CM) using a 20 mL syringe connected to a blunt fill needle.</li>
	<li>Add 50-100 mL of normal medium to the medium reservoir.</li>
	<li>Add 15 mL of exosome-depleted medium to the cell compartment by removing the old medium and adding fresh exosome-depleted medium using a 20 mL syringe connected to a blunt fill needle.</li>
	<li>Fill the medium reservoir of the bioreactor flask with normal medium up to 500 mL and keep the flask in the incubator (5% CO2, 37 &#176;C) for another week. 
	NOTE: The culture can be continued for more than a year. For step 2.2, the CM from the first harvest will not be used for exosome isolation and is discarded. For the 2nd and subsequent harvest, the CM is kept for exosome isolation.</li>
</ol>
3. Exosome Isolation onto a Sucrose Cushion
<img alt="Figure 2" class="xfigimg" src="/files/ftp_upload/58814/58814fig2.jpg" /> 
Figure 2: Isolation and characterization of exosomes. (A) Pre-clearing harvested conditioned medium (CM) from dead cells and cell debris. (B) Isolating exosomes from CM onto sucrose cushion. (C) Washing step to remove sucrose and contaminating proteins. (D) Isolated exosomes were then subjected to physicochemical, biochemical and morphological characterization. <a href="https://www.jove.com/files/ftp_upload/58814/58814fig2large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<ol>
	<li>Pre-clear the CM (from step 2.2) by differential centrifugation and filtration as follows.
	<ol>
		<li>Centrifuge at 500 x g for 5 min at 4 &#176;C. Transfer the supernatant into a new tube and discard the pellet. Repeat this centrifugation step once more, recovering the supernatant and discarding the pellet.</li>
		<li>Centrifuge the supernatant from step 3.1.1 at 2,000 x g for 15 min and 4 &#176;C and then discard pellet. Filter the recovered supernatant once through 0.22 &#181;m filters.</li>
	</ol>
	</li>
	<li>During pre-clearing, prepare 25% (w/w) sucrose solution in deuterium oxide by accurately weighing out 1.9 g (&#177; 0.001 g) of sucrose in a universal tube, and then topping up with deuterium oxide until the weight reaches 7.6 g (&#177; 0.001 g).</li>
	<li>Fill up an ultracentrifuge tube (see Table of Materials) with 22.5 mL of pre-cleared CM. Make up the CM to 22.5 mL with 0.22 &#181;m-filtered PBS if the current volume is less than that.</li>
	<li>Place a glass pipette (see Table of Materials) in the tube and, through it, add 3 mL of sucrose solution so that the solution forms a separate layer beneath the CM.</li>
	<li>Carefully place the tube containing layered CM/sucrose solution into the bucket of a swing-out rotor (see Table of Materials), and secure the bucket into the rotor.</li>
	<li>Place the rotor into the ultracentrifuge (see Table of Materials) and spin at 100,000 x g for 1.5 h at 4 &#176;C.</li>
	<li>Collect 2 mL of the sucrose layer and add this to an ultracentrifuge bottle (see Table of Materials) containing 20 mL of filtered PBS for a washing step.</li>
	<li>Place the tubes into a fixed-angle rotor (see Table of Materials) and spin at 100,000 x g for 1.5 h at 4&#176;C.</li>
	<li>Carefully remove the supernatant with a 10 mL serological pipette and resuspend the pellet with 400 &#181;L filtered PBS. Keep this exosome stock at 4 &#176;C or -80 &#176;C for short-term and long-term storage respectively.</li>
</ol>
4. Characterization of Exosome Size and Yield by Nanoparticle Tracking Analysis (NTA)
<ol>
	<li>Make 1:1,000-1:50,000 dilutions of the exosome stock in 1 mL (minimum 750 &#181;L) volume so as to obtain 20-80 particles in the viewing frame of the NTA instrument (see Table of Materials) display.</li>
	<li>Inject the diluted exosome stock into the NTA instrument sample chamber using a 1 mL syringe, and insert the temperature probe of a thermometer into the temperature probe inlet.</li>
	<li>Set the NTA software (see Table of Materials) for recording as follows: 3 standard measurements, 30 s each, manual temperature option unchecked; and enter the dilution factor under the Advanced tab.</li>
	<li>Set the camera level to 13 and run the capture script on the NTA software, injecting a fresh batch of sample and entering the temperature of the sample chamber when prompted after each reading.</li>
	<li>Set the threshold to 4 for the subsequent analysis part, and note the average modal size and particle concentration of the exosome stock from the measurements.</li>
</ol>
5. Characterization of Exosome Purity by Particle:Protein Ratio Determination
<ol>
	<li>Measure the protein content of the exosome stock by a bicinchoninic acid (BCA) protein assay kit (see Table of Materials) as follows.
	<ol>
		<li>Prepare the defined standards.
		<ol>
			<li>Prepare the standard of the highest concentration (500 &#181;g/mL) by adding 45 &#181;L of BSA stock solution (2 mg/mL &#8211; provided in the assay kit) to a microcentrifuge tube, and make it up to 180 &#181;L with PBS.</li>
			<li>Fill 8 microcentrifuge tubes with 90 &#181;L of PBS.</li>
			<li>Make serial dilutions (factor: 0.5) by taking 90 &#181;L from the highest BSA standard and adding this into the 1st microcentrifuge tube with PBS (mix well), then taking 90 &#181;L from this tube and adding it into the 2nd microcentrifuge tube.</li>
			<li>Repeat this until the 7th microcentrifuge tube. The 8th tube will be just PBS (i.e., the blank: 0 &#181;g/mL).</li>
		</ol>
		</li>
		<li>Prepare the exosome samples by making 1:2 dilution of samples with PBS in a total volume of 90 &#181;L (45 &#181;L of sample, 45 &#181;L of PBS).</li>
		<li>Prepare the BCA working reagent mix.
		<ol>
			<li>Calculate the total volume of BCA working reagent mix needed (50 &#181;L per well, in duplicates, including standards).</li>
			<li>Mix the individual BCA reagents according to the following ratio: 25 parts reagent A: 24 parts reagent B: 1 part reagent C.</li>
		</ol>
		</li>
		<li>Perform the assay and analysis.
		<ol>
			<li>Add 40 &#181;L of each standard and exosome sample prepared above into a well of a 96-well plate (duplicates for each standard and sample). 
			NOTE: Since this is a colorimetric assay, proper pipetting technique is crucial to achieve accurate results. Change pipettes after adding each standard/sample replicate into each of the wells</li>
			<li>Add 50 &#181;L of the protein assay working reagent mix into each well, and incubate the plate at 37 &#176;C for 30 min. 
			NOTE: To minimize deviations between replicates, add the protein assay working reagent into the 1st replicate of a standard/sample, followed by the 2nd replicate of the same sample/standard, before adding it to the 1st replicate of another sample/standard.</li>
			<li>Measure the absorbance at 562 nm on the plate reader (see Table of Materials).</li>
			<li>Plot a standard curve from the absorbance values of the standards, and work out the protein concentration in each sample using the equation of the curve.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Calculate the particle:protein ratio by dividing the exosome yield obtained earlier with the protein concentration of the exosome stock measured above.</li>
</ol>
6. Characterization of Exosomal Marker Expression by Flow Cytometry
<ol>
	<li>Incubate 40 &#181;L of exosomes (&#8805;1x1011 particles/mL) with 10 &#181;L of aldehyde/sulphate latex beads (undiluted from stock) for 15 min at room temperature (RT).</li>
	<li>Add 5 &#181;L of 100 &#181;M BSA solution (see Table of Materials) to the exosome-bead mixture to achieve a 10 &#956;M final concentration and incubate for 15 min at RT.</li>
	<li>Add 1 mL of PBS and incubate for 75 min at RT in a microcentrifuge tube with mild agitation on a rocking shaker (~150 rpm).</li>
	<li>Centrifuge the suspension at 580 x g for 5 min at RT and discard the supernatant.</li>
	<li>Resuspend the pellet with 1 mL of 100 mM glycine solution (see Table of Materials) and incubate for 30 min at RT.</li>
	<li>Centrifuge the suspension for 5 min at 580 x g. Discard the supernatant and resuspend the pellet with 1 mL of 3% FBS/PBS (see Table of Materials).</li>
	<li>Repeat this washing step and resuspend the pellet in 350 &#181;L of 3% FBS/PBS.</li>
	<li>Divide the suspension into 7 tubes, each containing 50 &#181;L of suspension and incubate them with fluorophore-conjugated anti-CD81, anti-CD9 and anti-CD63 antibodies and their corresponding isotype controls (1:10 dilution), respectively, for 45 min at 4 &#176;C. Keep 1 of the tubes as an unstained control but undergoing the same processing.</li>
	<li>Add 1 mL of 3% FBS/PBS to each tube, centrifuge for 5 min at 580 x g and discard the supernatant.</li>
	<li>Resuspend the pellet with 200-400 &#181;L of 3% FBS/PBS and analyze the sample on the flow cytometer (see Table of Materials) under the appropriate channels.</li>
</ol>
7. Characterization of Exosome Morphology by Transmission Electron Microscopy (TEM)
<ol>
	<li>Fix exosome aqueous dispersions at proper concentrations such as 1010 p/mL in fixing solution (see Table of Materials) for 15 min.</li>
	<li>Place the samples on 300 mesh carbon coated copper grids and leave to air dry.</li>
	<li>Negatively stain the samples with 0.22 &#181;m-filtered aqueous uranyl acetate (see Table of Materials) for 4 min followed by two 50% methanol/H2O wash (see Table of Materials).</li>
	<li>Air dry the sample.</li>
	<li>Observe the samples under TEM (see Table of Materials). Set the accelerating voltage at 80 kV and the spot size at 2. Use objective aperture with all samples.</li>
</ol>
8. siRNA Encapsulation into Exosomes by Electroporation
<ol>
	<li>Pre-chill the electroporation cuvette (see Table of Materials) on ice for 30 min before electroporation.</li>
	<li>Mix 7.0 &#181;g of exosomes (32 &#181;L from 7 x 1012 p/mL stock in PBS) with 0.33 &#181;g of siRNA (12 &#181;L from 2 &#181;M stock in RNase-free water) in the microcentrifuge tube. Make up the volume to 150 &#181;L with citric acid buffer (see Table of Materials). The exosome to siRNA molar ratio is 1:60 in this case.</li>
	<li>Transfer the mixture to electroporation cuvette. Cap the cuvette and place it in the cuvette holder of the electroporator (see Table of Materials). Rotate the turning wheel 180&#176; clockwise. 
	NOTE: The wheel must be turned completely to the locked position, in order for the cuvette to contact the electrodes.</li>
	<li>Select the desired electroporation program (e.g., X-01, X-05, A-20, T-20, T-30, etc.) and start electroporation by pressing the Start button. 
	NOTE: A successful pulse is indicated by showing &#8220;OK&#8221; on the display.</li>
	<li>Once electroporated, remove the cuvette after turning back the wheel 180&#176; counter-clockwise. Withdraw the sample from the cuvette with the plastic pipette for further processing.</li>
</ol>
9. Removal of Free siRNA Using Size Exclusion Chromatography (SEC)
<ol>
	<li>Equilibrate the SEC column (2.9 cm [H] x 1.3 cm [W]; see Table of Materials) by passing 3.5 mL of filtered PBS twice.</li>
	<li>Dissolve 150 &#956;L of electroporated sample in 350 &#956;L of filtered PBS and transfer this to the SEC column to perform the free siRNA removal.</li>
	<li>Collect the first 500 &#956;L fraction that eluted from the column (F0).</li>
	<li>Add 500 &#956;L of filtered PBS to the column and collect the next 500 &#956;L fraction (F1).</li>
	<li>Repeat the above step until a total of 10 x 500 &#956;L fractions (up to F9) is collected. F1 and F2 should contain the siRNA-encapsulated exosomes.</li>
	<li>Wash the column with filtered PBS (twice, at least) to remove any sample residues.</li>
</ol>
10. In Vitro Uptake of siRNA-Loaded Exosomes into PANC-1 Cells
<ol>
	<li>Seed PANC-1 cells in 24-well flat-bottom plates (see Table of Materials) at a density of 50,000 cells per well 24 h prior to the uptake study and incubate the cells in the incubator (5% CO2, 37 &#176;C).</li>
	<li>Electroporate HEK-293 exosomes (7.0 &#956;g) with Atto655-siRNA (0.33 &#956;g) as per Step 8.</li>
	<li>Purify electroporated exosome as per Step 9 and resuspend in 100 &#956;L of PBS.</li>
	<li>Add 50 &#956;L of the electroporated exosomes to PANC-1 cell and incubate at 37 &#176;C and 5% CO2 for 4 h.</li>
	<li>Collect cells after incubation.</li>
	<li>Wash the cells with 1 mL of sterile PBS and resuspend in 200 &#956;L of PBS in polystyrene round-bottom tube (see Table of Materials).</li>
	<li>Analyze cells by flow cytometer (see Table of Materials) with 10,000 events acquired per sample. 
	NOTE: Un-electroporated exosome-siRNA mixture samples and untreated cells with filtered PBS were used as controls.</li>
</ol>

The authors declare that they have no competing financial interests.

Obtaining a decent exosome yield from cultured cells, which are enough for several rounds of in vitro or in vivo studies, is still a challenge. According to the manufacturer, the bioreactor flasks were intended for production of antibodies and proteins with high yield from culture of various immortalized cell lines. This allows the cells to continuously enrich the culture medium with the desired product, resulting in a concentrated conditioned medium (CM) in the cell-compartment. Theoretically, the same concept would be beneficial in exosome production from various cell lines, and indeed culturing these cells in the bioreactor flasks was demonstrated to significantly increase the exosome yield40. The large medium reservoir continuously supplies nutrients to and removes wastes from the cell compartment through a 10 kDa semi-permeable membrane, allowing prolonged culture without requiring a large volume of medium to be in contact with the cells, or regular flasks changing, which can ultimately save the overall cost and labor of high-scale exosome production40. It was also demonstrated that the morphology, phenotype as well as the immunomodulatory functions of exosomes isolated cells long-term bioreactor flasks cultures are similar to that sourced from cells cultured in regular 75 cm2 flasks40. Culture of other immortalized cell lines as exosome sources in the bioreactor flask would therefore help increase their exosome yield while maintaining their integrity and function. This form of culture is however not applicable to primary cells with limited division cycles, and those that cannot be cultured in high density.
Since harvest of the CM is done weekly, and the cells in culture were never passaged, it can be assumed that the cells in the bioreactor flask are not growing in a monolayer like the regular cell culture. They are most likely to form clusters with necrotic centers, or simply detach from the surface and die when the cells are too confluent for a monolayer. Visual inspection of the cell compartment of the bioreactor flask is not possible to confirm this assumption, but is reflected by the large number of dead cells obtained during the CM harvesting. Regular removal of poorly adherent and non-viable cells from the bioreactor flask can prevent the build-up of materials on the semi-permeable membrane that can adversely affect the exchange of gas, nutrients and waste between the cell compartment and the medium reservoir, thus allowing prolonged culture in the bioreactor flasks for &#62;6 months40. In this context, this non-regularity of cell growth in the bioreactor flasks is ideal as we speculate that it mimics the actual condition of tumor growth in vivo more closely than the conventional monolayer cell culture, and it is hoped that the exosomes produced by the cancer cells in the bioreactor flask would be more similar to that secreted by tumors in vivo. This would be particularly beneficial in studies looking into the role of tumor-derived exosomes in the progression of the tumor pathology. Tumor-derived exosomes have been reported to intrinsically and preferentially home to their tissue of origin32, therefore having exosomes produced in a system mimicking their in vivo production would also be desirable in studies looking at exploring the passive targeting ability of exosomes as drug nanocarriers.
The P:P ratio was reported as a parameter to assess the purity of isolated exosomes from contaminating proteins from the culture medium of physiological fluids from which exosomes were sourced from41. The P:P ratio of 8.3 &#177; 1.7 &#215; 1010 p/&#181;g obtained in this study falls within the high purity range proposed in the study. This ratio highlights the danger of using protein concentration to express the yield or dose of exosomes isolated or used in downstream studies respectively, as this does not reflect the true amount of exosomes available in the sample given the problem of protein contamination during isolation. NTA via instruments such as NanoSight, which measures the concentration of exosomes in terms of particle number, is a more sensible and accurate way of quantifying exosomes.
Highly accurate weighing during the preparation of the 25% sucrose solution in deuterium oxide is crucial as this method is a density-based isolation. Exosomes have a rather narrow range of flotation density in sucrose solution so accurate preparation of the sucrose cushion will reduce contamination of non-exosomal vesicles such as apoptotic bodies or Golgi-derived vesicles during isolation42. It is advised not to keep leftover sucrose solution and using it even after one day so as to avoid risk of factors that can alter its density such as loss or addition of water in the solution by either evaporation or condensation of air in the tube. Use of a swing-out rotor is also essential during centrifugation onto the sucrose cushion to allow even migration of exosomes from the CM to the sucrose solution.
Withdrawing the sucrose solution post-centrifugation is also a delicate step, and it involves finding a compromise between maximizing the amount of exosomes recovered, and not too much that protein from culture medium is introduced to the exosome sample withdrawn. The interface between the sucrose solution and the condition medium is where proteins from the culture medium would collect post-centrifugation, and can usually be seen as a dark brown ring that sits on the interface. In our hands, withdrawing 2 mL of the sucrose cushion from the initial 3 mL added is the optimum volume that agrees with the compromise mentioned above. The volumes described in this protocol are for the specific rotors used; therefore, it is advised to optimize the volume of sucrose to be withdrawn when scaling up or down the volumes for the types of rotors available in different facilities. It is also important to avoid the area right at the center of the bottom of the tube when withdrawing the sucrose, as this is where particles of higher density than sucrose will sediment and can usually be seen as an off-white pellet.
The washing step with a relatively large amount of PBS helps to further reduce the degree of protein contamination during exosome isolation41. This step is also essential in removing excess sucrose from the exosomes so as to avoid osmotic damage to the exosomes themselves or the biomolecules within the exosomal lumen, as well as reducing the risk of bacterial and/or fungal growth in the exosome stock. Preparing the sucrose solution in deuterium oxide rather than water helps to reduce the amount of sucrose needed to achieve the exosome flotation density for isolation, hence reducing the risk of both osmotic damage and microbial contamination. After the first centrifugation onto the sucrose cushion, the exosome-containing sucrose layer withdrawn and added to the PBS can be stored at 4 &#176;C and processed the following day if faced with time constraints.
To the best of our knowledge, the exosome/siRNA molar ratio is an important factor in determining the efficiency of electroporation. In this protocol, we used 1:60 as the exosome to siRNA molar ratio. As the encapsulation ability of different types of exosomes are different, we strongly suggest this to be optimized on a case-by-case basis. However, the encapsulation efficiency proposed herein can always be a parameter for selecting the optimal electroporation conditions.
In addition, aggregation of siRNA is believed to be one of the most common problem in electroporation. It is proven that electroporation can induce strong aggregation of siRNA, making it even harder to enter exosomes. siRNA aggregations are often mistakenly interpreted as encapsulation of siRNA into exosome therefore proper controls were used in this study as the formation of siRNA aggregates is unavoidable during electroporation28. The percentage encapsulation efficiency of our purification method was calculated by using normalized values to minimize the influence from other sources such as background noise, exosome and siRNA aggregations that would affect the data reliability. Based on our findings, there was negligible siRNA aggregations observed in the control sample i.e., using electroporated and un-electroporated siRNA.
This protocol has successfully demonstrated the encapsulation of siRNA into exosomes and their subsequent intracellular delivery of the siRNA to cancer cells in vitro. Therefore, various types of exosomes from different cell lines can be isolated and characterized using the proposed protocol, and subsequently loaded with various therapeutic siRNA for different types of oncogenic targets over-expressed in different cancers. An interesting application would be to explore the siRNA delivery and uptake efficiency using various permutations of exosome source-target cell pair in vitro. This can then be translated to animal models to assess the efficiency of both the delivery and therapeutic efficiency of siRNA-encapsulated exosomes in vivo.

Exosomes are a subtype of extracellular vesicles (EV) ranging from 50-200 nm in diameter, secreted by various cell types such as immune cells1,2, cancer cells3,4,5,6&#160;and stem cells7. Exosomes have also been shown to be present in various physiological fluids8,9,10,11. The combination of the inherent ability of exosomes to carry various biomolecules (e.g., RNA and proteins)12,13,14 and the effective delivery of these biomolecules into recipient cells15,16,17 attracted interest for their potential as nano-scale drug delivery vectors. Various small molecules that serve as anti-cancer and anti-inflammatory drugs have been demonstrated to be successfully loaded into exosomes and delivered to target cells18,19,20,21,22,23,24,25,26,27. Interestingly, nucleic acids such as siRNA28,29 and microRNA30 have also been successfully loaded into exosomes via electroporation and delivered to target cells.
Recently, RNA interference (RNAi) via small interfering RNA (siRNA) has gained more interest as the preferred mechanism in gene silencing due to its high specificity, potent effect, minimal side effects and ease of siRNA synthesis28,29. siRNAs are double-stranded RNA molecules ranging from 19 to 25 nucleotides in length that triggers sequence-specific catalytic mRNA knockdown. Due to its large molecular weight and polyanionic nature, passive uptake of naked siRNA into cells is hindered28,29. It is also not possible for naked siRNA to be injected into the systemic circulation due to rapid degradation by plasma nucleases31. Thus, encapsulation of siRNA in a nanocarrier would aid the effective delivery and uptake of siRNA into the target cells.
Exosomes are&#160;an ideal system for siRNA encapsulation as its structure is comprised of a hollow, aqueous core enveloped by a phospholipid bilayer. Exosomes not only have good stability in the blood but also have natural targeting properties to deliver functional RNA into cells32. The study conducted by Alvarez-Erviti et al. successfully demonstrated effective delivery of siRNA to the brains of mice using engineered exosomes with virtually no complications31. It is hypothesized that exosome-based therapy is relatively safer than other therapies as exosomes do not replicate endogenously as cells would and therefore do not exhibit metastatic properties15.
Various methods have been reported to successfully isolate exosomes from either cell culture or physiological fluids. The most popular method uses ultracentrifugation to pellet exosomes from the starting material31,32,33. This method can be quite harsh on exosomes and usually co-precipitates proteins from the sample. Combining ultracentrifugation with a density-based separation such as sucrose gradients is becoming more common, to reduce protein and non-exosomal contamination in the isolated exosomes19,34. Size-exclusion chromatography (SEC) allows separation of exosomes from other types of extracellular vesicles (EV) by size and can also result in minimal protein contamination but is limited by small amount of starting material it can process35,36. Immunoaffinity capture uses beads coated with antibodies that bind to exosomal surface proteins such as tetraspanins or other cell-specific marker that allows specific capture of exosomes rather than EVs or other proteins, as well as isolating sub-population of exosomes from whole samples, but again is limited by the amount of starting material and is costly36,37. Polymer-based precipitation of exosomes used to be popular too, but since it is a rather crude precipitation, it leads to a higher non-exosomal vesicle and protein contamination38,39.
Electroporation has been reported for its inefficiency as a method to load exosomes with siRNA due to protein aggregation15,28,31. Transfection-based approaches were demonstrated to have better loading efficiency and protein stability, but is undesirable due to its toxicity and side effects of transfection agents in altering cellular gene expression28. Thus, electroporation has been more widely used in siRNA loading into exosomes as it is a safer method. However, an optimized encapsulation method needs to be established in order to deliver adequate amounts of siRNA to the target site for a potent gene knockdown.
Here, we propose an exosome isolation protocol using density-based ultracentrifugation onto just a single 25% (w/w) sucrose cushion prepared in deuterium oxide, rather than a sucrose density gradient. This is a cost-effective method that circumvents the laborious density gradient preparation and allows processing of large volumes of starting material, yet results in intact exosomes of high yield and purity suitable for subsequent loading with siRNA. Fluorescent Atto655-conjugated non-specific siRNA was loaded into Human Embryonic Kidney cells (HEK-293 cells) derived exosomes via electroporation and delivered to human pancreatic adenocarcinoma (PANC-1) cancer cells in vitro.

<table><tbody><tr><td>&lt;strong&gt;Material &lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Sterile Newborn Calf Serum Heat Inactivated</td><td>First Link</td><td>08-05-850</td><td>500 ml</td></tr><tr><td>EMEM medium</td><td>Thermo Fisher Scientific</td><td>11090081</td><td>500 ml</td></tr><tr><td>Penicillin/Streptomycin</td><td>Thermo Fisher Scientific</td><td>15140-122</td><td>100 ml</td></tr><tr><td>GlutaMax</td><td>Thermo Fisher Scientific</td><td>35050-038</td><td>100 ml</td></tr><tr><td>Sucrose</td><td>Fisher Scientific</td><td>S/8600/60</td><td>1 kg</td></tr><tr><td>Deuterium oxide (D&lt;sub&gt;2&lt;/sub&gt;O)</td><td>Sigma-Aldrich</td><td>151882</td><td>250 g</td></tr><tr><td>1X Phosphate Buffered Saline&amp;nbsp;</td><td>Thermo Fisher Scientific</td><td>10010015</td><td>500 ml</td></tr><tr><td>Glycine</td><td>VWR Chemicals</td><td>101196X</td><td>1 kg</td></tr><tr><td>Sepharose CL-2B</td><td>GE Healthcare Life Sciences</td><td>17-0140-01</td><td>1 L; Particle Size 60 &amp;mu;m-200 &amp;mu;m</td></tr><tr><td>Trypsin-EDTA 0.05%</td><td>Thermo Fisher Scientific</td><td>25300096</td><td>100 ml</td></tr><tr><td>Aldehyde/sulfate latex beads</td><td>Thermo Fisher Scientific</td><td>A37304</td><td>4% w/v, 4 &amp;micro;m, 15 ml</td></tr><tr><td>MicroBCA kit</td><td>Thermo Fisher Scientific</td><td>23235</td><td></td></tr><tr><td>CD81 antibody (APC)</td><td>Thermo Fisher Scientific</td><td>17-0819-42</td><td>Lot: E15950-104. RRID: AB_11150235. 1:10 dilution in 50 &amp;micro;l sample</td></tr><tr><td>CD81 isotype (APC)</td><td>Thermo Fisher Scientific</td><td>17-4714-81</td><td>&amp;nbsp;Lot: 4291563. RRID: AB_763650. 1:10 dilution in 50 &amp;micro;l sample</td></tr><tr><td>CD9 antibody (FITC)</td><td>Thermo Fisher Scientific</td><td>11-0098-41</td><td>Lot: 4345870. RRID: AB_10698007. 1:10 dilution in 50 &amp;micro;l sample</td></tr><tr><td>CD9 isotype (FITC)</td><td>Thermo Fisher Scientific</td><td>11-4714-41</td><td>Lot: 4299784. RRID: AB_10598647. 1:10 dilution in 50 &amp;micro;l sample</td></tr><tr><td>CD63 antibody (PE)</td><td>Thermo Fisher Scientific</td><td>12-0639-41</td><td>Lot: 1930435. RRID: AB_2572564. 1:10 dilution in 50 &amp;micro;l sample</td></tr><tr><td>CD63 isotype (PE)</td><td>Thermo Fisher Scientific</td><td>12-4714-81</td><td>Lot: 1937696. RRID: AB_470059. 1:10 dilution in 50 &amp;micro;l sample</td></tr><tr><td>Atto655-siRNA</td><td>Eurogentec</td><td>&amp;nbsp;&amp;nbsp;&amp;nbsp; SQ-SIRNA</td><td>(Labelled-S) UGC-GCU-ACG-AUC-GAC-GAU-G55; (Unlabelled-AS) CAU-CGU-CGA-UCG-UAG-CGC-A55.</td></tr><tr><td>&lt;strong&gt;Name&lt;/strong&gt;</td><td>&lt;strong&gt;Company &lt;/strong&gt;</td><td>&lt;strong&gt;Catalog Number&lt;/strong&gt;</td><td>&lt;strong&gt;Comments&lt;/strong&gt;</td></tr><tr><td>&lt;strong&gt;Equipment &lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>Millex-GP Syringe Filter Unit 0.22&amp;nbsp;&amp;micro;m</td><td>Millipore</td><td>SLGP033RS</td><td></td></tr><tr><td>CELLine AD1000 bioreactor flasks</td><td>Wheaton</td><td>WCL1000ad</td><td></td></tr><tr><td>Ultracentrifuge</td><td>Beckman Coulter</td><td>Optima XPN-80</td><td></td></tr><tr><td>Swing-out rotor</td><td>Beckman Coulter</td><td>SW45 Ti</td><td></td></tr><tr><td>Fixed-angle rotor</td><td>Beckman Coulter</td><td>Type 70 Ti</td><td></td></tr><tr><td>Ultracentrifuge tubes</td><td>Beckman Coulter</td><td>355631</td><td>Polycarbonate. Max. fill 32 ml</td></tr><tr><td>Ultracentrifuge bottles</td><td>Beckman Coulter</td><td>355618</td><td>Polycarbonate. Min. fill 16 ml, max. fill 25 ml</td></tr><tr><td>NanoSight</td><td>Malvern</td><td>LM10</td><td>Software: NanoSight NTA v3.2</td></tr><tr><td>Flow Cytometer</td><td>BD Biosciences</td><td>FACSCalibur</td><td></td></tr><tr><td>Centrifuge</td><td>Eppendorf</td><td>5810R</td><td></td></tr><tr><td>Plate reader</td><td>BMG Labtech</td><td>FLUOstar Omega</td><td></td></tr><tr><td>Flow cytometry tubes</td><td>BD Biosciences, Falcon</td><td>352052</td><td></td></tr><tr><td>Microfuge tubes</td><td>Starlab</td><td>S1615-5500</td><td>1.5 ml</td></tr><tr><td>Cell culture flasks</td><td>Fisher Scientific</td><td>156499</td><td>75 cm&lt;sup&gt;2&lt;/sup&gt;</td></tr><tr><td>Transmission electron microscope</td><td>FEI Electron Optics</td><td>Philips CM 12</td><td>with Tungsten filament and a Veleta - 2k &amp;times; 2k side-mounted TEM CCD Camera (Olympus, Japan)</td></tr><tr><td>Amaxa Nucleofector I</td><td>Lonza</td><td>Nucleofector I</td><td>with Amaxa&amp;rsquo;s Nucleofector Kits</td></tr><tr><td>24-well flat-bottom plates</td><td>Corning</td><td>Costar</td><td></td></tr><tr><td>Blunt fill needle</td><td>BD Biosciences</td><td>305180</td><td>18G x 1 1/2&quot; (1.2 mm x 40 mm)</td></tr><tr><td>Glass pipettes</td><td>Fisher Scientific</td><td>1156-6963</td><td></td></tr><tr><td>&lt;strong&gt;Name&lt;/strong&gt;</td><td>&lt;strong&gt;Company &lt;/strong&gt;</td><td>&lt;strong&gt;Catalog Number&lt;/strong&gt;</td><td>&lt;strong&gt;Comments&lt;/strong&gt;</td></tr><tr><td>&lt;strong&gt;Reagents &lt;/strong&gt;</td><td></td><td></td><td>&lt;strong&gt;Composition &lt;/strong&gt;</td></tr><tr><td>Normal medium</td><td></td><td></td><td>Eagle&#039;s Minimum Essential Medium supplemented with 10% foetal bovine serum (FBS), 1% penicillin/streptomycin and 1% GlutaMax.</td></tr><tr><td>Exosome-depleted medium</td><td></td><td></td><td>Eagle&#039;s Minimum Essential Medium supplemented with 10% exosome-depleted FBS (see below), 1% penicillin/streptomycin and 1% GlutaMax.</td></tr><tr><td>Exosome-depleted FBS</td><td></td><td></td><td>Subject FBS to ultracentrifugation at 100,000 g for 18 h at 4&amp;deg;C. The FBS supernatant post-centrifugation was collected and sterile-filtered using 0.22 &amp;micro;m filters.</td></tr><tr><td>25% w/w sucrose cushion</td><td></td><td></td><td>Add 1.9 g (&amp;plusmn; 0.001 g) of sucrose in a universal tube, and top up with D&lt;sub&gt;2&lt;/sub&gt;O until the weight reaches 7.6 g (&amp;plusmn; 0.001 g). This makes ~6ml of the 25% w/w sucrose cushion.</td></tr><tr><td>3% FBS/PBS</td><td></td><td></td><td>Add 1.5 ml exosome-depleted FBS to 48.5 ml 1X PBS to prepare 50 ml of 3% FBS/PBS.</td></tr><tr><td>100 &amp;micro;M BSA solution</td><td></td><td></td><td>Prepare 1mM BSA solution by adding 0.3325 g to 50 ml PBS. Make 1:10 dilution of this stock to obtain 100 &amp;micro;M BSA solution. Make 5-10 &amp;micro;l aliqouts of this 100 &amp;micro;M BSA solution (for single use) and store them at -20&amp;deg;C. All BSA solution should be stored at -20&amp;deg;C, and discard solutions that have undergone &amp;ge;2 freeze-thaw cycles.</td></tr><tr><td>100 mM glycine solution</td><td></td><td></td><td>Add 0.375 g of glycine to 50 ml PBS to obtain 100 mM glycine solution, store at 4&amp;deg;C.</td></tr><tr><td>Citric acid buffer with EDTA</td><td></td><td></td><td>Mix 0.1954 g citric acid and 0.2087 g disodium phosphate in 50 mL of deionised water. Add EDTA to 0.1 mM. Adjust pH to 4.4.</td></tr><tr><td>Fixing solution</td><td></td><td></td><td>Prepare formaldehyde/glutaraldehyde, 2.5% (w/v) each in 0.1 M sodium cacodylate buffer, and adjust pH to 7.4.</td></tr><tr><td>Aqueous uranyl acetate</td><td></td><td></td><td>Prepare 25% (v/v) uranyl acetate in methanol.</td></tr><tr><td>50% methanol/H2O</td><td></td><td></td><td>Mix methanol and H2O 1:1 (v/v).</td></tr><tr><td>SEC Column packed with Sepharose CL-2B</td><td></td><td></td><td>Dilute 37.5 ml Sepharose CL-2B resin with 12.5 ml PBS to obtain 75% Sepharose CL-2B solution. Pour the Sepharose CL-2B solution into a column of dimension 2.9 cm [H] x 1.3 cm [W]. Pour the Sepharose CL-2B to 3-4 mm above the stated height, and then press it down to the stated height with the filter for optimal packing.</td></tr></tbody></table>

preparation of exosomes for sirna delivery to cancer cells

Extracellular vesicles, in particular exosomes, have recently gained interest as novel drug delivery vectors due to their biological origin, abundance, and intrinsic capability in intercellular delivery of various biomolecules. This work establishes an isolation protocol to achieve high yield and high purity of exosomes for siRNA delivery. Human Embryonic Kidney cells (HEK-293 cells) are cultured in bioreactor flasks and the culture supernatant (hereon referred to as conditioned medium) is harvested on a weekly basis to allow for enrichment of HEK-293 exosomes. The conditioned medium (CM) is pre-cleared of dead cells and cellular debris by differential centrifugation and is subjected to ultracentrifugation onto a sucrose cushion followed by a washing step, to collect the exosomes. Isolated HEK-293 exosomes are characterized for yield, morphology and exosomal marker expression by nanoparticle tracking analysis, protein quantification, electron microscopy and flow cytometry, respectively. Small interfering RNA (siRNA), fluorescently labeled with Atto655, is loaded into exosomes by electroporation and excess siRNA is removed by gel filtration. Cell uptake in PANC-1 cancer cells, after 24 h incubation at 37 &#176;C, is confirmed by flow cytometry. HEK-293 exosomes are 107.0 &#177; 8.2 nm in diameter. The exosome yield and particle-to-protein ratio (P:P) ratio are 6.99 &#177; 0.22 &#215; 1012 particle/mL and 8.3 &#177; 1.7 &#215; 1010 particle/&#181;g, respectively. The encapsulation efficiency of siRNA in exosomes is ~ 10-20%. Forty percent of the cells show positive signals for Atto655 at 24 h post-incubation. In conclusion, exosome isolation by ultracentrifugation onto sucrose cushion offers a combination of good yield and purity. siRNA could be successfully loaded into exosomes by electroporation and subsequently delivered into cancer cells in vitro. This protocol offers a standard procedure for developing siRNA-loaded exosomes for efficient delivery to cancer cells.

The physicochemical characterization of exosomes isolated from HEK-293 cells (HEK-293 Exo) are summarized in Table 1. The size measured using nanoparticle tracking analysis (NTA) instrument was 107.0 &#177; 8.2 nm. Exosome yield from the HEK-293 cells, also analyzed using the NTA instrument, was 6.99 &#177; 0.22 x 1012 p/mL from ~24 mL of CM (obtained from 2 rounds of harvest). Purity of the HEK-293 Exo assessed by calculating the particle-to-protein ratio&#160;(P:P) was 8.3 &#177; 1.7 &#215; 1010 p/&#181;g.
The size distribution of isolated HEK-293 Exo&#160;is shown in Figure 3A. Morphological analysis using transmission electron microscopy (TEM) showed the HEK-293 Exo were spherical structures slightly above 100 nm in size (Figure 3B). This result agrees with that from NTA measurement (Figure 3A). The isolated HEK-293 Exo&#160;were positive for CD81, CD9 and CD63, which are canonical markers used to identify vesicles as exosomes (Figure 3C).
For purification of exosomes using size exclusion chromatography (Figure 4), the percentage recovery of exosomes was calculated by dividing the total exosome particle number recovered in the 10 fractions collected (F0-F9) with the initial exosome particle number used, while the percentage recovery of siRNA was calculated by dividing the total fluorescence intensity obtained from F3, F4 and F5 with the total fluorescence intensity obtained from all 10 fractions collected. The recovery of exosome and siRNA post-purification was calculated as 75.0% and 80.4%, respectively. The encapsulation efficiency of siRNA in exosomes was ~10-20%, calculated using the siRNA standard curve established (Figure 4C).
Qualitative analysis of in vitro&#160;uptake of exosomes loaded with the fluorescent Atto655-siRNA by flow cytometry showed that PANC-1 cells treated with siRNA-encapsulated exosomes recorded the largest shift in fluorescence signal (Figure 5A). PANC-1 cells treated with siRNA-encapsulated exosomes recorded a higher percentage of population positive for the Atto655 signal (39.4%) compared to that treated with unloaded exosomes and siRNA mixture (0.56%), which corroborated the observation above (Figure 5B). The degree of cellular uptake of siRNA (expressed as the fold difference in mean fluorescence intensity (MFI) values from that of untreated cells) was also observed to be significantly higher in PANC-1 cells treated with siRNA-encapsulated exosomes (MFI fold difference = 5.1) compared to that treated with the exosome-siRNA mixture (MFI fold difference = 1.1) (Figure 5C). These observations demonstrated that the siRNA-encapsulated exosomes were internalized by the PANC-1 cells and that they effectively delivered the siRNA intracellularly.
<img alt="Figure 3" class="xfigimg" src="/files/ftp_upload/58814/58814fig3.jpg" /> 
Figure 3: Biochemical and morphology analysis of HEK-293 exosomes. (A) Size distribution of HEK-293 exosomes using Nanoparticle Tracking Analysis (NTA). The curve shows a superimposed histogram from 3 different captures at 30 s interval with red areas denoting standard deviation between measurements (n = 3). (B) Transmission Electron Microscopy (TEM) images of the na&#239;ve HEK-293 exosomes. Scale bar: 100 nm. (C) Detection of exosomal markers CD81, CD9 and CD63 using flow cytometry on HEK-293 exosomes. Exosomes were coupled to aldehyde/sulphate latex beads prior to detection. Exosome-beads complex were subsequently stained with fluorophore-conjugated anti-CD81, anti-CD9 and anti-CD63 antibodies. Degree of expression of the markers are expressed as the fold difference in median fluorescence intensity (MFI) values from that of the control (exosome-beads complex stained with the corresponding isotype). Values are expressed as mean &#177; SD, where n = 3. <a href="https://www.jove.com/files/ftp_upload/58814/58814fig3large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 4" class="xfigimg" src="/files/ftp_upload/58814/58814fig4.jpg" /> 
Figure 4: Exosome purification post-electroporation. (A) Elution profiles (F0-F9) of Atto655-siRNA and electroporated exosomes using size exclusion chormatography. (B) NTA analysis of both Atto655-siRNA and exosome from F0 to F9 using size exclusion chormatography. (C) The calibration curve of Atto655 labelled siRNA. Fluorescence intensities were obtained by&#160;plate reader at Ex/Em: 640-10/680 nm; Gain 2800. Values are expressed as mean &#177; SD (n = 3). <a href="https://www.jove.com/files/ftp_upload/58814/58814fig4large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 5" class="xfigimg" src="/files/ftp_upload/58814/58814fig5.jpg" /> 
Figure 5: Cellular uptake of siRNA-encapsulated exosomes into PANC-1 cells at 4 h. (A) Histograms comparing cellular uptake of unloaded exosomes + siRNA mixture and siRNA-encapsulated exosomes. (B) Comparison of the uptake of unloaded exosomes + siRNA mixture at 4h by pseudocolor plot. (C) The fold difference in mean fluorescence intensity (MFI) values of the samples tested compared to that of untreated cells. Values are expressed as mean &#177; SD, where n = 3. *** P &#60; 0.001. NS: not significant. One-way ANOVA was used for statistical analysis. <a href="https://www.jove.com/files/ftp_upload/58814/58814fig5large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Exosome</td>
			<td>Size1,2 
			(nm)</td>
			<td>Yield1,2,3 
			(p/mL)</td>
			<td>[Protein]2,4 
			(&#181;g/mL)</td>
			<td>Particle-to-protein (P:P) ratio5 
			(p/&#181;g)</td>
		</tr>
		<tr>
			<td>HEK-293</td>
			<td>107.0 &#177; 8.2</td>
			<td>6.99 &#177; 0.22 x 1012</td>
			<td>84.3 &#177; 9.8</td>
			<td>8.3 &#177; 1.7 x 1010&#160; &#160;</td>
		</tr>
		<tr>
			<td colspan="5">1 Measured using nanoparticle tracking analysis (NTA instrument) 
			2 Values are expressed as mean &#177; SD, where n=3 
			3 Yield was obtained by cell-conditioned medium pooled from 2 rounds of harvesting from bioreactor flasks (~24 mL) 
			4 Measured using a protein assay kit 
			5 Value obtained by using formula: P:P ratio = Yield / [Protein]</td>
		</tr>
	</tbody>
</table>
Table 1: Physicochemical characterization of exosomes.

Watch this Scientific Journal Video about Preparation of Exosomes for siRNA Delivery to Cancer Cells at JoVE.com

Preparation of Exosomes for siRNA Delivery to Cancer Cells

An exosome is a new generation of drug delivery carriers. We established an exosome isolation protocol with high yield and purity for siRNA delivery. We also encapsulated fluorescently labelled non-specific siRNA into exosomes and investigated the cellular uptake of siRNA-loaded exosomes in cancer cells.

Extracellular vesicles, in particular exosomes, have recently gained interest as novel drug delivery vectors due to their biological origin, abundance, ...

preparation-of-exosomes-for-sirna-delivery-to-cancer-cells

Research

JoVE Journal

Cancer Research

24.8K Views.  King's College London. An exosome is a new generation of drug delivery carriers. We established an exosome isolation protocol with high yield and purity for siRNA delivery. We also encapsulated fluorescently labelled non-specific siRNA into exosomes and investigated the cellular uptake of siRNA-loaded exosomes in cancer cells.

Video: Preparation of Exosomes for siRNA Delivery to Cancer Cells

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Ablation of androgen receptor (AR) signaling by androgen deprivation is the goal of the first line of therapy for prostate cancer that initially results in cancer regression. However, in a significant number of cases, the disease progresses to advanced, castration-resistant prostate cancer (CRPC), which has limited therapeutic options and is often aggressive. Distant metastasis is mostly observed at this stage of the aggressive disease. CRPC is treated by a second generation of AR pathway inhibitors that improve survival initially, followed by the emergence of therapy resistance. Neuroendocrine prostate cancer (NEPC) is a rare variant of prostate cancer (PCa) that often develops as a result of therapy resistance via a transdifferentiation process known as neuroendocrine differentiation (NED), wherein PCa cells undergo a lineage switch from adenocarcinomas and show increased expression of neuroendocrine (NE) lineage markers. In addition to the genomic alterations that drive the progression and transdifferentiation to NEPC, epigenetic factors and microenvironmental cues are considered essential players in driving disease progression. This manuscript provides a detailed protocol to identify the epigenetic drivers (i.e., small non-coding RNAs) that are associated with advanced PCa. Using purified microRNAs from formalin-fixed paraffin-embedded (FFPE) metastatic tissues and corresponding serum-derived extracellular vesicles (EVs), the protocol describes how to prepare libraries with appropriate quality control for sequencing microRNAs from these sample sources. Isolating RNA from both FFPE and EVs is often challenging because most of it is either degraded or is limited in quantity. This protocol will elaborate on different methods to optimize the RNA inputs and cDNA libraries to yield most specific reads and high-quality data upon sequencing.

Therapy resistance often develops in patients with advanced prostate cancer, and in some cases, cancer progresses to a lethal subtype called neuroendocrine prostate cancer. Assessing the small non-coding RNA-mediated molecular changes that facilitate this transition would allow better disease stratification and identification of causal mechanisms that lead to development of neuroendocrine prostate cancer.

Ablation of androgen receptor (AR) signaling by androgen deprivation is the goal of the first line of therapy for prostate cancer that initially results ...

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Small interfering RNA (siRNA) can be used to suppress gene expression, thereby providing a new avenue for the treatment of various diseases. However, the successful implementation of siRNA therapy requires the use of delivery platforms that can overcome the major challenges of siRNA delivery, such as enzymatic degradation, low intracellular uptake and lysosomal entrapment. Here, a protocol for the preparation and use of a biocompatible and effective siRNA delivery system is presented. This platform consists of polyethylenimine (PEI) and arginine (Arg)-grafted porous silicon microparticles, which can be loaded with siRNA by performing a simple mixing step. The silicon particles are gradually degraded over time, thereby triggering the formation of Arg-PEI/siRNA nanoparticles. This delivery vehicle provides a means for protecting and internalizing siRNA, without causing cytotoxicity. The major steps of polycation functionalization, particle characterization, and siRNA loading are outlined in detail. In addition, the procedures for determining particle uptake, cytotoxicity, and transfection efficacy are also described.

Delivery remains the main challenge for the therapeutic implementation of small interfering RNA (siRNA). This protocol involves the use of a multifunctional and biocompatible siRNA delivery platform, consisting of arginine and polyethylenimine grafted porous silicon microparticles.

Small interfering RNA (siRNA) can be used to suppress gene expression, thereby providing a new avenue for the treatment of various diseases. However, the ...

Bioengineering

An Enrichment Method for Small Extracellular Vesicles Derived from Liver Cancer Tissue

Small extracellular vesicles (sEVs) derived from tissue can reflect the functional status of the source cells and the characteristics of the tissue's interstitial space. The efficient enrichment of these sEVs is an important prerequisite to the study of their biological function and a key to the development of clinical detection techniques and therapeutic carrier technology. It is difficult to isolate sEVs from tissue because they are usually heavily contaminated. This study provides a method for the rapid enrichment of high-quality sEVs from liver cancer tissue. The method involves a four-step process: the incubation of digestive enzymes (collagenase D and DNase &#921;) with tissue, filtration through a 70 &#181;m cell strainer, differential ultracentrifugation, and filtration through a 0.22 &#181;m membrane filter. Owing to the optimization of the differential ultracentrifugation step and the addition of a filtration step, the purity of the sEVs obtained by this method is higher than that achieved by classic differential ultracentrifugation. It provides an important methodology and supporting data for the study of tissue-derived sEVs.

Here we describe the enrichment of small extracellular vesicles derived from liver cancer tissue through an optimized differential ultracentrifugation method.

Small extracellular vesicles (sEVs) derived from tissue can reflect the functional status of the source cells and the characteristics of the tissue's ...

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Prion diseases result from the misfolding of the normal, cellular prion protein (PrPC) to an abnormal protease resistant isomer called PrPRes. The emergence of prion diseases in wildlife populations and their increasing threat to human health has led to increased efforts to find a treatment for these diseases. Recent studies have found numerous anti-prion compounds that can either inhibit the infectious PrPRes isomer or down regulate the normal cellular prion protein. However, most of these compounds do not cross the blood brain barrier to effectively inhibit PrPRes formation in brain tissue, do not specifically target neuronal PrPC, and are often too toxic to use in animal or human subjects. 
We investigated whether siRNA delivered intravascularly and targeted towards neuronal PrPC is a safer and more effective anti-prion compound. This report outlines a protocol to produce two siRNA liposomal delivery vehicles, and to package and deliver PrP siRNA to neuronal cells. The two liposomal delivery vehicles are 1) complexed-siRNA liposome formulation using cationic liposomes (LSPCs), and 2) encapsulated-siRNA liposome formulation using cationic or anionic liposomes (PALETS). For the LSPCs, negatively charged siRNA is electrostatically bound to the cationic liposome. A positively charged peptide (RVG-9r [rabies virus glycoprotein]) is added to the complex, which specifically targets the liposome-siRNA-peptide complexes (LSPCs) across the blood brain barrier (BBB) to acetylcholine expressing neurons in the central nervous system (CNS). For the PALETS (peptide addressed liposome encapsulated therapeutic siRNA), the cationic and anionic lipids were rehydrated by the PrP siRNA. This procedure results in encapsulation of the siRNA within the cationic or anionic liposomes. Again, the RVG-9r neuropeptide was bound to the liposomes to target the siRNA/liposome complexes to the CNS. Using these formulations, we have successfully delivered PrP siRNA to AchR-expressing neurons, and decreased the PrPC expression of neurons in the CNS.

The goal of this protocol is to use cationic/anionic liposomes with a neuro-targeting peptide as a CNS delivery system to enable siRNA to cross the BBB. The optimization of a delivery system for treatments, like siRNA, would allow for more treatment options for prion and other neurodegenerative diseases.

Prion diseases result from the misfolding of the normal, cellular prion protein (PrPC) to an abnormal protease resistant isomer called PrPRes.  The ...

Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

The discovery of alterations in the EGFR and ALK genes, amongst others, in NSCLC has driven the development of targeted-drug therapy using selective tyrosine kinase inhibitors (TKIs). To optimize the use of these TKIs, the discovery of new biomarkers for early detection and disease progression is mandatory. These plasma-isolated exosomes can be used as a non-invasive and repeatable way for the detection and follow-up of these biomarkers. One ml of plasma from 12 NSCLC patients, with different mutations and treatments (and 6 healthy donors as controls), were used as exosome sources. After RNAse treatment, in order to degrade circulating miRNAs, the exosomes were isolated with a commercial kit and resuspended in specific buffers for further analysis. The exosomes were characterized by western blotting for ALIX and TSG101 and by transmission electron microscopy (TEM) analysis, the standard techniques to obtain biochemical and dimensional data of these nanovesicles. Total RNA extraction was performed with a high yield commercial kit. Due to the limited miRNA-content in exosomes, we decided to perform retro-transcription PCR using an individual assay for each selected miRNA. A panel of miRNAs (30b, 30c, 103, 122, 195, 203, 221, 222), all correlated with NSCLC disease, were analyzed taking advantage of the remarkable sensitivity and specificity of Real-Time PCR analysis; mir-1228-3p was used as endogenous control and data were processed according to the formula 2-&#916;&#916;ct 13. Control values were used as baseline and results are shown in logarithmic scale.

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

This protocol describes the feasibility to perform miRNA profiling in exosomes, released in plasma of NSCLC patients, through a commercial exosome isolation kit with Proteinase K and RNAse treatments, in order to avoid circulating miRNAs contamination and evaluate their biomarker features in NSCLC.

The discovery of alterations in the EGFR and ALK genes, amongst others, in NSCLC has driven the development of targeted-drug therapy using selective ...

Medicine

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

The success of siRNA as a targeted molecular medicine is dependent upon its efficient cytosolic delivery to cells within the tissue of pathology. Clinical success for treating previously &#8216;undruggable&#8217; hepatic disease targets with siRNA has been achieved. However, efficient tumor siRNA delivery necessitates additional pharmacokinetic design considerations, including long circulation time, evasion of clearance organs (e.g., liver and kidneys), and tumor penetration and retention. Here, we describe the preparation and in vitro physicochemical/biological characterization of polymeric nanoparticles designed for efficient siRNA delivery, particularly to non-hepatic tissues such as tumors. The siRNA nanoparticles are prepared by electrostatic complexation of siRNA and the diblock copolymer poly(ethylene glycol-b-[2-(dimethylamino)ethyl methacrylate-co-butyl methacrylate]) (PEG-DB) to form polyion complexes (polyplexes) where siRNA is sequestered within the polyplex core and PEG forms a hydrophilic, neutrally-charged corona. Moreover, the DB block becomes membrane-lytic as vesicles of the endolysosomal pathway acidify (&#60; pH 6.8), triggering endosomal escape and cytosolic delivery of siRNA. Methods to characterize the physicochemical characteristics of siRNA nanoparticles such as size, surface charge, particle morphology, and siRNA loading are described. Bioactivity of siRNA nanoparticles is measured using luciferase as a model gene in a rapid and high-throughput gene silencing assay. Designs which pass these initial tests (such as PEG-DB-based polyplexes) are considered appropriate for translation to preclinical animal studies assessing the delivery of siRNA to tumors or other sites of pathology.

Methods to prepare and characterize the physicochemical properties and bioactivity of neutrally-charged, pH-responsive siRNA nanoparticles are presented. Criteria for successful siRNA nanomedicines such as size, morphology, surface charge, siRNA loading, and gene silencing are discussed.

The success of siRNA as a targeted molecular medicine is dependent upon its efficient cytosolic delivery to cells within the tissue of pathology. Clinical ...

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Previous studies showed that knockdown of ITSN-1s (KDITSN), an endocytic protein involved in regulating lung vascular permeability and endothelial cells (ECs) survival, induced apoptotic cell death, a major obstacle in developing a cell culture system with prolonged ITSN-1s inhibition1. Using cationic liposomes as carriers, we explored the silencing of ITSN-1s gene in mouse lungs by systemic administration of siRNA targeting ITSN-1 gene (siRNAITSN). Cationic liposomes offer several advantages for siRNA delivery: safe with repeated dosing, nonimmunogenic, nontoxic, and easy to produce2. Liposomes performance and biological activity depend on their size, charge, lipid composition, stability, dose and route of administration3Here, efficient and specific KDITSN in mouse lungs has been obtained using a cholesterol and dimethyl dioctadecyl ammonium bromide combination. Intravenous delivery of siRNAITSN/cationic liposome complexes transiently knocked down ITSN-1s protein and mRNA in mouse lungs at day 3, which recovered after additional 3 days. Taking advantage of the cationic liposomes as a repeatable safe carrier, the study extended for 24 days. Thus, retro-orbital treatment with freshly generated complexes was administered every 3rd day, inducing sustained KDITSN throughout the study4. Mouse tissues collected at several time points post-siRNAITSN were subjected to electron microscopy (EM) analyses to evaluate the effects of chronic KDITSN, in lung endothelium. High-resolution EM imaging allowed us to evaluate the morphological changes caused by KDITSN in the lung vascular bed (i.e. disruption of the endothelial barrier, decreased number of caveolae and upregulation of alternative transport pathways), characteristics non-detectable by light microscopy. Overall these findings established an important role of ITSN-1s in the ECs function and lung homeostasis, while illustrating the effectiveness of siRNA-liposomes delivery in vivo.

Repeated retro-orbital injections of cationic liposomes/siRNA/ITSN-1s complexes in mice, every 72 hours for 24 days, efficiently deliver the siRNA duplex to the mouse lung microvasculature reducing ITSN-1s mRNA and protein expression by 75%. This technique is highly reproducible in an animal model, has no adverse effects and avoids fatalities.

Previous  studies showed that knockdown of ITSN-1s (KDITSN), an endocytic  protein involved in regulating lung vascular permeability and endothelial cells ...

Biology

siRNA Encapsulation into Exosomes Using Electroporation: An Electric Pulse Based Technique to Load siRNA into Exosomes

Source: Faruqu, F. N. et al. <a href="https://www.jove.com/video/58814" target="_blank">Preparation of Exosomes for siRNA Delivery to Cancer Cells.</a> J. Vis. Exp. (2018)
This video describes an electroporation-based method for encapsulating siRNA into exosomes. The siRNA-loaded exosomes can then be used for therapeutic applications.

Source: Faruqu, F. N. et al. Preparation of Exosomes for siRNA Delivery to Cancer Cells. J. Vis. Exp. (2018)
This video describes an electroporation-based ...

JoVE Encyclopedia of Experiments

Urinary Tract Cancer

In vitro studies

Exosome Isolation: A Technique to Separate Exosomes from the Plasma of Non-small Cell Lung Cancer Patients

Source: Giallombardo, M., et al. <a href="https://www.jove.com/v/53900/exosomal-mirna-analysis-non-small-cell-lung-cancer-nsclc-patients">Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients&#39; Plasma Through qPCR: A Feasible Liquid Biopsy Tool.</a> J. Vis. Exp.&#160;(2016).
The plasma-isolated exosomes can be used as a non-invasive and repeatable way for the detection and follow-up of the biomarkers for early detection and disease progression. This video describes the protocol for the separation of exosomes from the plasma samples of non-small cell lung cancer patients, which could be used for DNA and protein extractions.

Source: Giallombardo, M., et al. Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients&#39; Plasma Through qPCR: A Feasible Liquid Biopsy ...

Lung Cancer

In vitro study

RNA Extraction Assay: A Method to Extract RNA from miRNA Transfected Lung Cancer Cells

Source: Hossian, A. K. M. N. et al., <a href="https://www.jove.com/v/59460/analysis-combinatorial-mirna-treatments-to-regulate-cell-cycle">Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis</a>. J. Vis. Exp. (2019).
This video describes the RNA extraction protocol from miRNA transfected lung cancer cells. This approach can be used to identify a combinatorial miRNA treatment activity in halting the cell cycle and angiogenesis.

Source: Hossian, A. K. M. N. et al., Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis. J. Vis. Exp. (2019).
This video ...